8-KCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Oct 20, 2011)

Filed October 20, 2011For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K report on October 20, 2011, detailing amendments to its bylaws that became effective on October 14, 2011. These amendments primarily focus on revising the procedures for shareholders to nominate directors and propose other business matters at company meetings. The changes aim to provide greater transparency and disclosure requirements for shareholders seeking to put forth proposals or director nominations. Key revisions include updated notice periods, enhanced disclosure requirements regarding the identity, ownership, and interests of proposing shareholders (including derivative instruments and competitor interests), and stricter requirements for director nominees themselves, such as submitting questionnaires and representations. These adjustments appear to be in line with corporate governance best practices and aim to ensure a more robust and informed shareholder engagement process.

Key Highlights

  • 1Abbott Laboratories amended its bylaws on October 14, 2011.
  • 2The amendments revise procedures for shareholder director nominations and proposals.
  • 3Enhanced disclosure requirements are now in place for proposing shareholders.
  • 4Shareholders must provide updated information on their identity, ownership, and voting interests.
  • 5Additional disclosures are required regarding competitor interests and derivative instruments.
  • 6Director nominees must now submit questionnaires and provide representations to the company.
  • 7Notice timing for special meetings has been adjusted.

Frequently Asked Questions

The main purpose is to revise and strengthen the procedures for shareholders who wish to nominate directors or propose other business matters at Abbott Laboratories' shareholder meetings, requiring more detailed disclosures from such shareholders and nominees.

Shareholders making proposals or nominations must provide updated information about their identity, ownership and voting interests in Abbott securities (including those from derivative instruments), any interests in competitors, and details about the proposal or nominee itself. For director nominees, this includes submitting a questionnaire and representations to the company.

No, the amendments clarify that these procedures do not limit shareholders' obligations or rights under the Securities Exchange Act of 1934 or Rule 14a-8.

For special meetings, notices must now be provided between 90 to 120 days prior to the meeting date. However, if a special meeting is announced less than 120 days prior, the notice must be received within ten days after the announcement of the meeting.